Galectin Therapeutics Inc (NASDAQ:GALT)
| Market Cap | 241.37M-22.9% |
| Revenue (ttm) | 0 |
| Net Income | -27.84M+31.0% |
| EPS | -0.43+33.3% |
| Shares Out | 65.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 103,095.918 |
| Open | 3.62 |
| Previous Close | 3.62 |
| Day's Range | 3.51 - 3.68 |
| 52-Week Range | 2.03 - 7.13 |
| Beta | 0.38 |
| Analysts | Buy |
| Price Target | 11.00(+200.14%) |
| Earnings Date | Nov 13, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About GALT
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$GALT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in GALT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GALT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GALT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New GALT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GALT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GALT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $6.01M |
| IWMiShares Russell 2000 ETF | $4.36M |
| VXFVanguard Extended Market ETF | $2.46M |
| IWOiShares Russell 2000 Growth ETF | $1.13M |
| VTWOVanguard Russell 2000 ETF | $1.09M |
| IWCiShares Micro-Cap ETF | $544.05K |
Estimated from each fund’s disclosed top holdings × AUM
GALT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GALT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score